BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會


BIONET Corp. - Advanced Cell Therapies in the COVID-19 Pandemic/post-Pandemic Era

Advanced Cell Therapies in the COVID-19 Pandemic/post-Pandemic Era

Date:July 21 (Wed) 2021

Since the end of 2019, the pandemic caused by the outbreak of the novel coronavirus (COVID-19) has affected everyone. With active research for treatment around the world, the development of cell therapy has accelerated. Through the regenerative and immuno-modulation functions of stem cells, clinical trials for the treatment for COVID-19 infection have also increased rapidly.

This webinar has invited doctors and scholars from Indonesia, Japan, Malaysia, Singapore, Thailand, and Taiwan, to share the status of cell therapy in their fields and to provide insights on how cell therapy has become a new hope of treatment for severely-affected patients in the pandemic and post-pandemic era.


Topic / Speaker
15:40 - 15:49

Opening Remarks
Advanced Cell Therapies in the COVID-19 Pandemic/post-Pandemic Era.

Dr. Tokiko Nagamura-Inoue / MD, PhD, Hospital professor.
Research hospital, Inst. of Medical Science, Univ. of Tokyo, Japan.

Section1  Moderator:

Dr. Chang-Yao Tsao / MD, PhD, Professor.
Internal of Medicine, Director, Immune Cell Therapy Unit,Chung Shan Medical University, Taichung, Taiwan.
15:49 - 16:03

Human Umbilical Cord-Derived Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome.

Dr.Hon-Kan Yip/Professor Level Attending Physician.
Kaohsiung Chang Gung Memorial Hospital, Taiwan.
16:03 - 16:16

Mesenchymal stem cell therapy for severe COVID-19: Sharing experience from Thailand

Dr. Sithakom Phusanti
Deputy Director and Chief of Information Officer (CIO)/ Physician (Hematologist, Internist)
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Thailand.
16:16 - 16:31

Applications of mesenchymal stem cells in immune disorders and lung injury, including severe COVID-19 infection.

Dr. Kang-Hsi Wu/ MD, Vice superintendent.
Chung Shan Medical University Hospital, Taichung, Taiwan.
16:31 - 16:45

Umbilical cord mesenchymal stromal cell as critical COVID-19 adjuvant therapy.

Professor Ismail H Dilogo/ MD, PhD.
Stem Cell Medical Technology Integrated Service Unit, Cipto
Mangunkusumo Central Hospital, Faculty of Medicine University Indonesia, Jakarta, Indonesia.
16:45 - 16:54

Section1 Panel Discussion

Moderator: Dr. Chang-Yao Tsao
Panelists: Dr.Hon-Kan Yip/Dr. Sithakom Phusanti/Dr. Kang-Hsi Wu/Professor Ismail H Dilogo
16:54 - 16:54

Section2 Moderator:

Dr. Tokiko Nagamura-Inoue / MD, PhD, Hospital professor.
Research hospital, Inst. of Medical Science, Univ. of Tokyo, Japan.
16:54 - 17:05

The promise of cell therapy for pediatric acute/chronic lung disease: clinical case sharing.

Dr. Pei-Chen Tsao/ Director of neonatal intensive care unit.
Taipei Veterans General Hospital, Taiwan.
17:05 - 17:13

Stem Cells Technology 4.0 in Anti-Ageing and Anti-COVID

Professor Phan Toan-Thang / Founding Director and Chief Scientific Officer
Cell Research Corporation, Singapore.
17:13 - 17:29

The anti-inflammatory and Immunomodulatory actions of human umbilical cord derived mesenchymal stem cells: Clinical Perspectives.

Dr. Chin Sze-Piaw / Clinical and Research Advisor
CYTOPEUTICS & Honorary Fellow of the Centre for Stem Cell Research (CSCR), Faculty of Medicine and Health Sciences, University Tunku Abdul Rahman (UTAR), Malaysia.
17:29 - 17:40

Section2 Panel Discussion/ Final Conclusions

Moderator: Dr. Tokiko Nagamura-Inoue
Panelists: Dr. Pei-Chen Tsao/Dr. Ivor Lim/Dr. Chin Sze-Piaw
Organizer: Chris Tsai-Chairman of BIONET Corp. /Dr. Wen-Chien Lee- President of Asian Federation of Biotechnology.


Company Info

Company Name: BIONET Corp.
Address: No.28, Ln.36, Xinhu 1st Rd., Neihu Dist., Taipei City 11494, Taiwan


Name: Yvonne Lin
Title: Senior Public Relations Executive
Phone: (Work)(02)2795-1777#1567

Company Type


Company Introduction

BIONET Corp. was established in 1999 as the pioneer company in the field of stem cell applications in Taiwan. BIONET has focused in three areas: “Cell Therapy”、” Precision Medicine/Genetic Testing” and “Scientific Informatics”. By providing cells, genetic testing, skin care products and other technologies, BIONET serves more than 40% of newborns and 90% of reproductive medicine centers in Taiwan while expanding services to 17 countries oversea meeting the health needs of more than 1.4 million customers at different stages in life.